117718-93-1

Basic information

• Product Name: 6-BROMO-8-MORPHOLINOIMIDAZOL[1,2-A]PYRAZINE
• Synonyms: 6-BROMO-8-MORPHOLINOIMIDAZOL[1,2-A]PYRAZINE;4-{6-broMoiMidazo[1,2-a]pyrazin-8-yl}Morpholine
• CAS NO: 117718-93-1
• Molecular Formula: C₁₀H₁₁BrN₄O
• Molecular Weight: 283.12
• Mol File: 117718-93-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.79 g/cm³
• Refractive Index: 1.743
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-BROMO-8-MORPHOLINOIMIDAZOL[1,2-A]PYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-8-MORPHOLINOIMIDAZOL[1,2-A]PYRAZINE(117718-93-1)
• EPA Substance Registry System: 6-BROMO-8-MORPHOLINOIMIDAZOL[1,2-A]PYRAZINE(117718-93-1)

Safety Data

• Hazardous Substances Data: 117718-93-1(Hazardous Substances Data)

Usage

General Description

6-Bromo-8-morpholinoimidazo[1,2-a]pyrazine is a chemical compound with the molecular formula C8H8BrN5O. It is a heterocyclic organic compound that contains a bromine atom, a morpholino group, and an imidazopyrazine ring system. 6-BROMO-8-MORPHOLINOIMIDAZOL[1,2-A]PYRAZINE is mainly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. Its unique structure and reactivity make it a valuable intermediate for the production of various biologically active molecules. Additionally, it is a potential drug candidate in the field of medicinal chemistry due to its diverse pharmacophore and potential therapeutic properties.

InChI:InChI=1/C10H11BrN4O/c11-8-7-15-2-1-12-9(15)10(13-8)14-3-5-16-6-4-14/h1-2,7H,3-6H2

Upstream product

• 107-20-0 2-chloroethanal 
• 117719-17-2 5-bromo-3-morpholin-4-ylpyrazin-2-ylamine 
• 110-91-8 morpholine 
• 63744-22-9 6,8-dibromoimidazo[1,2-a]pyrazine 

Relevant articles and documents

Synthesis and biological evaluation of novel 8-morpholinoimidazo[1,2-a]pyrazine derivatives bearing phenylpyridine/phenylpyrimidine-carboxamides

Herein we designed and synthesized three series of novel 8-morpholinoimidazo[1,2-a] pyrazine derivatives bearing phenylpyridine/phenylpyrimidine-carboxamides (compounds 12a-g, 13a-g and 14a-g). All the compounds were evaluated for their IC50 values against three cancer cell lines (A549, PC-3 and MCF-7). Most of the target compounds exhibited moderate cytotoxicity against the three cancer cell lines. Two selected compounds 14b, 14c were further tested for their activity against PI3Kα kinase, and the results indicated that compound 14c showed inhibitory activity against PI3Kα kinase with an IC50 value of 1.25 μM. Structure-activity relationships (SARs) and pharmacological results indicated that the replacement of the thiopyranopyrimidine with an imidazopyrazine was beneficial for the activity and the position of aryl group has a significant influence to the activity of these compounds. The compounds 13a-g in which an aryl group substituted at the C-4 position of the pyridine ring were more active than 12a-g substituted at the C-5 position. Moreover, the cytotoxicity of compounds 14a-g bearing phenylpyrimidine-carboxamides was better than that of the compounds 12a-g, 13a-g bearing phenylpyridine-carboxamides. Furthermore, the substituents on the benzene ring also had a significant impact on the cytotoxicity and the pharmacological results showed that electron donating groups were beneficial to the cytotoxicity.

Synthesis and Antibronchospastic Activity of 8-Alkoxy- and 8-(Alkylamino)imidazopyrazines

Theophylline still occupies a dominant place in asthma therapy.Unfortunatly its adverse central nervous system (CNS) stimulant effects can dramatically limit its use, and adjustments in the dosage are often needed.We have synthesized a new series of imidazopyrazine derivatives which are much more potent bronchodilators than theophylline in vivo and do not exhibit the CNS stimulatory profile.In vitro studies on isolated rat uterus and guinea pig trachea confirm the high potentialities of these derivatives. 6-Bromo-8-(methylamino)imidazopyrazine-3-carbonitrile (23) is identified as the most potent compound of the series.As i n the case of theophylline, phosphodiesterase inhibition appears unlikely to be the unique mechanism of the action of this series of heterocycles.